Bone Density in Patients With Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
Inje University
ClinicalTrials.gov Identifier:
NCT00540267
First received: October 4, 2007
Last updated: November 3, 2008
Last verified: October 2008
  Purpose

People with chronic mental disorder such as schizophrenia and alcohol abuse are high risk groups for developing osteoporosis.

To evaluate the prevalence of bone mineral density in men patients with schizophrenia with alcohol abuse, the investigators will compare bone mineral density between patient with schizophrenia with and without alcohol abuse.


Condition Intervention
Schizophrenia
Alcohol Abuse
Other: No Intervention

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Bone Mineral Density in the Korean Patients With Chronic Schizophrenia With Alcohol Abuse

Resource links provided by NLM:


Further study details as provided by Inje University:

Primary Outcome Measures:
  • The change of bone mineral density [ Time Frame: cross sectional and prospective ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The effects of Smoking and antipsychotic drug on BMD [ Time Frame: Cross sectional Study ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: November 2007
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Schizophrenia
Chronic schizophrenia with aged 18-80 years
Other: No Intervention
No Intervention

Detailed Description:

People with schizophrenia has been known as a high risk groups for developing osteoporosis, because of lack of exercise, poor nutrition and high rate of smoking. Those with alcohol abuse may be higher risk group than one with schizophrenia without alcohol abuse, because they frequently have several medical problems such as liver dysfunction, Vitamin D deficiency, hyperparathyroidism and those medical condition increase risk for developing osteoporosis. Also alcohol itself can increase bone loss too by disturbing bone remodeling and enhancing bone fragility. To compare the prevalence of bone mineral density in patients with schizophrenia with alcohol abuse to those without alcohol problem, we will investigate BMD in large population of Korean patients with those illnesses.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

people with schizophrenia, gaed between 18-80 years, with no endocrine disorder

Criteria

Inclusion Criteria:

  • DSM-IV diagnosis of schizophrenia
  • Onset of illness more than 5 years.

Exclusion Criteria:

  • No severe Medical and endocrinological disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00540267

Locations
Korea, Republic of
Joo-Cheol Shim
Busan, Korea, Republic of, 614-735
Sponsors and Collaborators
Inje University
Investigators
Study Director: Joo-Cheol Shim, MD,PhD Inje University
  More Information

No publications provided

Responsible Party: Joo Shim, Imje University Busan Paik Hospital
ClinicalTrials.gov Identifier: NCT00540267     History of Changes
Other Study ID Numbers: BMD07, Korea Health 21 R&D Project
Study First Received: October 4, 2007
Last Updated: November 3, 2008
Health Authority: Korea: Food and Drug Administration

Keywords provided by Inje University:
Schizophrenia
Alcohol Abuse
Bone Density

Additional relevant MeSH terms:
Schizophrenia
Alcoholism
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders

ClinicalTrials.gov processed this record on August 01, 2014